Related Experiment Videos
BMS-275291. Bristol-Myers Squibb
1Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114, USA. poulakiv@hotmail.com
Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
Summary
BMS-275291, a matrix metalloproteinase (MMP) inhibitor, shows promise for cancer treatment by targeting tumor growth without common side effects. Clinical trials are evaluating its efficacy as an adjunct to chemotherapy for non-small cell lung cancer.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Matrix metalloproteinases (MMPs) are implicated in tumor growth and metastasis.
- First-generation MMP inhibitors have shown side effects related to MMP-mediated shedding events.
- BMS-275291 is a novel MMP inhibitor designed to avoid these specific side effects.
Purpose of the Study:
- To evaluate BMS-275291, an MMP inhibitor, for potential cancer treatment.
- To assess the safety and efficacy of BMS-275291 in patients with non-small cell lung cancer.
- To determine the potential of BMS-275291 as an adjunct to standard chemotherapy.
Main Methods:
- Phase II/III clinical trials were conducted.
- BMS-275291 was administered as an adjunct to standard chemotherapy.
- Non-small cell lung cancer patients were enrolled in the trials.
Main Results:
- BMS-275291 demonstrated inhibition of MMPs associated with tumor growth and spread.
- The compound did not inhibit MMP-mediated shedding events, potentially reducing side effects.
- Financial analysts provided market predictions regarding launch dates and peak sales.
Conclusions:
- BMS-275291 represents a potentially improved MMP inhibitor for cancer therapy.
- Further data from phase II/III trials are anticipated to impact market perceptions.
- The drug's targeted inhibition profile may offer a better safety and efficacy balance.